Autres langues Zai Lab Limited

Actions

ZLAB

US98887Q1040

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 06/08/2026			Varia. 5j.	Varia. 1 janv.
20,88 ^USD	+13,66 %		+14,66 %	+18,37 %

06/08	Transcript : Zai Lab Limited, Q2 2026 Earnings Call, Aug 06, 2026
06/08	Les actions asiatiques cotées aux États-Unis sous forme d'ADR progressent lors de la séance de jeudi	MT

Autres langues

06/08	Asian Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
06/08	Zai Lab Shares Rise After Q2 Beat
06/08	Zai Lab Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	Earnings Flash (ZLAB) Zai Lab Limited Reports Q2 Revenue $106.3M, vs. FactSet Est of $103.9M
06/08	Earnings Flash (ZLAB) Zai Lab Limited Reports Q2 Loss of $0.46 per ADS, vs. FactSet Est of $-0.68
06/08	Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates
03/08	Zai Lab Receives FDA Orphan Drug Designation for Zocilurtatug Pelitecan in Neuroendocrine Carcinomas
03/08	U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)
29/07	Asian Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading
22/07	Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026
29/06	Zai Lab Insider Sold Shares Worth $428,545, According to a Recent SEC Filing
17/06	Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan in Pulmonary Neuroendocrine Carcinomas
16/06	Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug
16/06	Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas
10/06	Asian Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading
09/06	Zai Lab Says China Approves Tivdak for Cervical Cancer Treatment
09/06	Zai Lab Receives China NMPA Approval For TIVDAK For Treatment Of Recurrent Or Metastatic Cervical Cancer
09/06	Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
29/05	Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Up for Week
22/05	Zai Lab President, COO Josh Smiley to Depart
22/05	Zai Lab Ousts COO Josh Smiley
22/05	Zai Lab Announces Changes to Senior Leadership Team
22/05	Zai Lab Limited Announces Departure of Josh Smiley as President and COO, Effective May 22, 2026
19/05	Zai Lab Insider Sold Shares Worth $1,986,875, According to a Recent SEC Filing
18/05	Asian Equities Traded in the US as American Depositary Receipts Lower in Monday Trading